Guggenheim Capital
RXII

Guggenheim Capital’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Guggenheim Capital’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-55,646
Closed -$26K – 2997
2016
Q2 		$26K Buy
55,646
+2,345
+4% +$1.1K ﹤0.01% 2794
2016
Q1 		$73K Buy
53,301
+16,447
+45% +$22.5K ﹤0.01% 2781
2015
Q4 		$54K Buy
36,854
+1,266
+4% +$1.86K ﹤0.01% 2889
2015
Q3 		$56K Sell
35,588
-774
-2% -$1.22K ﹤0.01% 2846
2015
Q2 		$62K Buy
36,362
+1,837
+5% +$3.13K ﹤0.01% 2946
2015
Q1 		$48K Buy
34,525
+2,600
+8% +$3.62K ﹤0.01% 2933
2014
Q4 		$48K Buy
31,925
+8,299
+35% +$12.5K ﹤0.01% 2921
2014
Q3 		$48K Sell
23,626
-33,994
-59% -$69.1K ﹤0.01% 2932
2014
Q2 		$177K Sell
57,620
-1,805
-3% -$5.54K ﹤0.01% 2926
2014
Q1 		$148K Buy
59,425
+11,393
+24% +$28.4K ﹤0.01% 2954
2013
Q4 		$238K Buy
48,032
+2,128
+5% +$10.5K ﹤0.01% 2789
2013
Q3 		$105K Buy
45,904
+11,084
+32% +$25.4K ﹤0.01% 2847
2013
Q2 		$78K Buy
+34,820
New +$78K ﹤0.01% 2854

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock Investment Management
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
TIAA CREF Investment Management
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Guggenheim Capital's RXII Position: Q3 2016 in Review

Guggenheim Capital sold out of GALENA BIOPHARMA INC COM (RXII) in Q3 2016, closing a stake of 55,646 shares — an estimated $26K sold.

Guggenheim Capital first reported a position in RXII in Q2 2013 and held it in 13 quarters. The position peaked at $238K in Q4 2013. 92 funds tracked by Wall St. Rank hold RXII as of Q3 2016.

  • Guggenheim Capital reported no remaining GALENA BIOPHARMA INC COM position as of Q3 2016 after selling out during the quarter.
  • Guggenheim Capital sold 55,646 GALENA BIOPHARMA INC COM shares in Q3 2016, an estimated $26K.
  • Guggenheim Capital first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 13 quarters.
  • Guggenheim Capital's GALENA BIOPHARMA INC COM position peaked at $238K in Q4 2013.
  • 92 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q3 2016.

Based on Guggenheim Capital's 13F filing for Q3 2016, filed 15 Nov 2016.